Clinical Information

This panel is designed to follow the current National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer by evaluating EGFR, ALK and other driver genetic alterations using multiplex testing. Targeted agents may be available for treatment based on the genetic alteration profile identified.

Tissue sections were examined by pathological review for relevant tumor area for analysis.  DNA-based next generation sequencing (NGS) was performed using Archer® VariantPlex to detect frequently occurring mutations in exons 18-21 of the EGFR gene, exons 2-4 of the KRAS gene, exon 15 of the BRAF gene, exon 20 of the ERBB2 gene, and high-level MET amplification. RNA-based NGS was performed using Archer® FusionPlex platform to detect MET exon 14 skipping events along with prominent ALK, NTRK, RET, and ROS1 fusions. This test also has the potential to uncover additional genetic alterations on MET, BRAF, FGFR1/2/3, NRG1 fusion and EGFRvIII if present. These rare alterations must be integrated into the clinical context for interpretation for limited specimens were available for validation.